VIP (vasoactive intestinal peptide) regulatory status

FDA and compounding

Not an FDA approved drug in the United States. An aviptadil and phentolamine combination is approved in some European countries for erectile dysfunction, and aviptadil was studied under FDA authorized COVID-19 trials but never authorized or approved. Vasoactive intestinal peptide appears on the FDA 503A bulk drug substances list as Category 1 (nominated and under evaluation), so 503A pharmacies may compound it while FDA finishes its review; it has not been placed on the bulks list and was not part of the April 2026 Category 2 removals or the July 2026 advisory committee recommendations.

WADA

WADA status unclear

Access path

1. Prescription from a licensed provider filled by a 503A compounding pharmacy as an intranasal spray, while VIP remains in FDA Category 1.
2. Not available as an FDA approved product.
3. Products labeled research use only are not lawful for human use and are not verified for purity.

Full VIP (vasoactive intestinal peptide) page: evidence, dosing in the literature, and sources